Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Moderna ( (MRNA) ) just unveiled an update.
Moderna announced its 2024 product sales reached $3.0 to 3.1 billion, driven by its COVID-19 vaccine business, and reported a cash balance of approximately $9.5 billion. Looking ahead, the company plans to reduce cash costs by $1 billion in 2025 and anticipates further cost reductions in 2026. The company expects revenues of $1.5 to 2.5 billion in 2025 and aims for several product approvals and data readouts across its prioritized programs, including vaccines for respiratory viruses and other diseases, with potential significant financial and industry impact.
More about Moderna
Moderna is a leading company in the field of mRNA medicine, focusing on the development of vaccines and therapeutics for infectious diseases, immuno-oncology, rare diseases, and autoimmune diseases. With a global team and a strong emphasis on innovation, Moderna aims to transform disease treatment and prevention through its mRNA technology platform.
YTD Price Performance: 0.60%
Average Trading Volume: 8,223,292
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $16.26B
Learn more about MRNA stock on TipRanks’ Stock Analysis page.
